MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Home・Akcijų sąrašas・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

493.89 -2.59

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

492.34

Max

511.43

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-72M -114M
Pardavimai	74M 287M
Pelno marža	-39.75
Darbuotojai	528
EBITDA	-68M -106M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+24.62% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-25

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.4B 12B
Ankstesnė atidarymo kaina	496.48
Ankstesnė uždarymo kaina	493.89

Naujienos nuotaikos

By Acuity

50%

183 / 361 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

263.2 / 277.1 Palaikymas ir pasipriešinimas

Madrigal Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-13 19:05; UTC

Pagrindinės rinkos jėgos

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

2026-01-13 23:41; UTC

Rinkos pokalbiai

Nikkei May Rise on Japan Election Hopes -- Market Talk

2026-01-13 23:41; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-13 23:33; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

2026-01-13 23:13; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

2026-01-13 23:10; UTC

Įsigijimai, susijungimai, perėmimai

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

2026-01-13 23:03; UTC

Rinkos pokalbiai

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

2026-01-13 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

2026-01-13 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

2026-01-13 21:20; UTC

Įsigijimai, susijungimai, perėmimai

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

2026-01-13 21:15; UTC

Įsigijimai, susijungimai, perėmimai

VERSANT Completes Acquisition Of Free TV Networks >VSNT

2026-01-13 21:08; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

2026-01-13 20:39; UTC

Rinkos pokalbiai

Silver Settles at Another New High -- Market Talk

2026-01-13 20:21; UTC

Rinkos pokalbiai

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

2026-01-13 20:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

2026-01-13 19:08; UTC

Įsigijimai, susijungimai, perėmimai

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

2026-01-13 19:03; UTC

Uždarbis

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

2026-01-13 18:50; UTC

Uždarbis

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

2026-01-13 17:54; UTC

Rinkos pokalbiai

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2026-01-13 17:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

2026-01-13 17:49; UTC

Rinkos pokalbiai

Analysts Call For Potential Record Ethanol Output -- Market Talk

2026-01-13 17:38; UTC

Rinkos pokalbiai

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-13 17:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-01-13 17:19; UTC

Rinkos pokalbiai

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

2026-01-13 17:15; UTC

Rinkos pokalbiai

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Akcijų palyginimas

Kainos pokytis

Madrigal Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

24.62% į viršų

12 mėnesių prognozė

Vidutinis 636.22 USD 24.62%

Aukščiausias 900 USD

Žemiausias 527 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Madrigal Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Madrigal Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

263.2 / 277.1Palaikymas ir pasipriešinimas

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

183 / 361 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.